Key Takeaways:Hormonal transitions are now recognized as major mental health inflection points, yet care remains fragmented and underfunded. A new generation of femtech innovators are reframing mood disorders as part of hormonal health, not separate from it. For beauty and wellness brands, hormone literacy and mood-regulating innovation represent the next frontier of efficacy, trust, and consumer connection.The Hormone–Mental Connection The data linking hormonal transitions with depression and anxiety is undeniable, yet healthcare still treats them in silos. For example, four in 10 women experience mood-related symptoms during perimenopause, while 80% develop neuropsychiatric symptoms, most commonly hot flashes, cognitive dysfunction, and sleep disturbances.This gap isn’t just clinical; it’s systemic, extending from research to therapy. Samphire Neuroscience is a London-based neurotech start-up developing the first approved medical device for drug-free and hormone-free treatment of menstrual symptoms. Its co-founder and CEO, Dr. Emilė Radytė, explained to BeautyMatter that for a long time, women’s health was studied in fragments—reproduction over here, mental health over there—and the two rarely spoke to each other. “Hormonal cycles were often treated as background noise rather than central to how women feel, think, and function,” she said.Even though 76% of US therapists are women, few private practices are structured to protect their well-being—a symptom of a system that continues to externalize women’s care while undervaluing their health.